Article

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.

2023-03-01

Abstract excerpt

<title>Abstract</title> <p><bold>INTRODUCTION:</bold> PREDICT is an online tool that estimates the 10-year breast cancer overall survival (10OS) with different adjuvant treatment combination. EndoPredict® is a genetic biomarker to guide decision on adjuvant systemic therapy in hormone-positive early-stage breast cancer. No study had ever correlated the estimated outcomes of PREDICT and EndoPredict® results. <bold...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6fd6e24a-4be1-5d7a-9387-81c41aec555d
DOI: 10.21203/rs.3.rs-2591077/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.DOI 10.21203/rs.3.rs-2591077/v1Read

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancersSemantic proximity Read

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity Read

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.Semantic proximity Read

Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity Read

A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerSemantic proximity Read

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity Read

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancerSemantic proximity Read

Deep learning from HE slides to predict the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancerSemantic proximity Read

Multimodal histopathologic models stratify hormone receptor-positive early breast cancerSemantic proximity Read